Addex Therapeutics (ADXN) director discloses share and option holdings

Rhea-AI Filing Summary

Addex Therapeutics Ltd. director Vincent Michael Lawton has filed a Form 3 reporting his initial beneficial ownership in the company. He holds 2,507,987 shares of Common Stock listed on the SIX Swiss Exchange and a stock option award over 501,598 shares of Common Stock.

The stock options carry an exercise price of $0.064 per share, based on a CHF-to-USD exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026. These options began vesting in equal monthly installments over a four-year period starting January 8, 2024 and expire on January 7, 2034.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lawton Vincent Michael

(Last) (First) (Middle)

CHEMIN DES MINES 9

(Street)

GENEVA CH-1202

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

3a. Foreign Trading Symbol
[ADXN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,507,987(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-Option (Right to Buy)	01/08/2024(2)	01/07/2034	Common Stock	501,598	$0.064(3)	D

Explanation of Responses:

1. Represents 2,507,987 shares of Common Stock listed on SIX Swiss Exchange.

2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.

3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Lenaic Nathanael Teyssedou by power of attorney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Addex Therapeutics (ADXN) Form 3 filing report for Vincent Michael Lawton?

The Form 3 reports Vincent Michael Lawton’s initial beneficial ownership in Addex Therapeutics Ltd. It shows his direct holdings of common shares on the SIX Swiss Exchange and a stock option grant over additional shares with specified vesting and exercise terms.

How many Addex Therapeutics (ADXN) common shares does Vincent Michael Lawton report on Form 3?

He reports beneficial ownership of 2,507,987 shares of Addex Therapeutics Common Stock. A footnote clarifies these shares are listed on the SIX Swiss Exchange, giving a clear picture of his direct equity position in the company at the time of the filing.

What stock options does Vincent Michael Lawton hold in Addex Therapeutics (ADXN)?

He holds stock options over 501,598 shares of Addex Therapeutics Common Stock. Each option entitles him to purchase one ADXN share listed on the SIX Swiss Exchange, subject to the vesting schedule and the stated exercise price in the filing.

What are the vesting terms of Vincent Michael Lawton’s Addex Therapeutics (ADXN) stock options?

The stock options vest in equal monthly installments over a four-year period beginning on January 8, 2024. This gradual vesting structure links the realization of the option value to continued service and time, rather than providing immediate full exercisability.

What is the exercise price and expiry date of Vincent Michael Lawton’s Addex Therapeutics (ADXN) options?

The options have an exercise price of $0.064 per share, translated from CHF using a $1.2769 per CHF 1.00 rate as of March 12, 2026. They are scheduled to expire on January 7, 2034, defining a long-dated window for potential exercise.

On which exchange are Vincent Michael Lawton’s Addex Therapeutics (ADXN) shares listed?

The filing states that the 2,507,987 common shares reported are listed on the SIX Swiss Exchange. His stock options each grant the right to purchase one ADXN share that is also listed on the SIX Swiss Exchange, aligning equity exposure with that listing venue.